Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for LITS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2003. Start Trial.
Date Value
March 31, 2026 56.84M
December 31, 2025 81.85M
September 30, 2025 112.27M
June 30, 2025 16.93M
March 31, 2025 19.54M
December 31, 2024 22.10M
September 30, 2024 24.88M
June 30, 2024 33.02M
March 31, 2024 51.03M
December 31, 2023 59.49M
September 30, 2023 81.36M
June 30, 2023 24.62M
March 31, 2023 34.35M
December 31, 2022 48.37M
September 30, 2022 37.31M
June 30, 2022 52.41M
March 31, 2022 67.81M
December 31, 2021 73.33M
September 30, 2021 31.83M
June 30, 2021 49.47M
March 31, 2021 44.96M
December 31, 2020 73.50M
September 30, 2020 82.33M
June 30, 2020 78.22M
March 31, 2020 74.50M
Date Value
December 31, 2019 77.28M
September 30, 2019 47.28M
June 30, 2019 47.93M
March 31, 2019 37.88M
December 31, 2018 53.47M
September 30, 2018 39.76M
June 30, 2018 50.46M
March 31, 2018 32.91M
December 31, 2017 38.36M
September 30, 2017 43.57M
June 30, 2017 50.84M
March 31, 2017 54.90M
December 31, 2016 54.89M
September 30, 2016 42.33M
June 30, 2016 41.65M
March 31, 2016 46.91M
December 31, 2015 51.64M
September 30, 2015 55.94M
June 30, 2015 59.79M
March 31, 2015 64.96M
December 31, 2014 72.86M
September 30, 2014 37.61M
June 30, 2014 45.19M
March 31, 2014 52.52M
December 31, 2013 58.73M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
SELLAS Life Sciences Group, Inc. 137.66M
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M

Shareholders Equity (Quarterly) Related Metrics